Mounjaro (Tirzepatide) Pregnancy and Lactation Safety
Evidence-based guide to tirzepatide (Mounjaro) safety during pregnancy and breastfeeding, including FDA labeling, animal data, washout timing, and what remains unknown.
Is Mounjaro an FDA-Inspected Medication? Approval Status
Mounjaro is FDA-approved (May 2022) for type 2 diabetes, plus approved by EMA, MHRA, and Health Canada. See exact approval dates by country.
Mounjaro Safety Signals and FDA Actions: What the Evidence Shows
A clinician-grade review of tirzepatide (Mounjaro) safety signals, FDA black box warnings, postmarket adverse events, label revisions, and what prescribers should monitor.
Mounjaro in Special Populations: Transplant, HIV, and Other Complex Patient Groups
Evidence-based guide to using Mounjaro (tirzepatide) in special populations including transplant recipients, people living with HIV, older adults, and patients with renal or hepatic impairment.
Does TRICARE Cover Mounjaro? Formulary, Prior Authorization, and Appeal Steps
TRICARE covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization. Learn formulary tier placement, step therapy requirements, appeal steps for denials, and out-of-pocket cost options for military beneficiaries.
NMN and NR Safety for Adults 30 to 49: What the Clinical Evidence Shows
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety data in adults aged 30 to 49, covering dosing, side effects, drug interactions, and monitoring.
Does Cigna Cover NMN/NR (Nicotinamide Mononucleotide/Riboside)?
Learn whether Cigna plans cover NMN or NR, how FDA treats these supplements, and what randomized trials show about NAD+ levels and benefits.
NMN/NR Cost vs. Alternatives: Comparing NAD+ Precursor Prices and Value
A clinical comparison of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) costs against other NAD+ precursors, niacin, and IV NAD+ infusions, with an evidence-boundary review and dosing context.
NMN and NR Safety in Adults 65 and Older: What the Evidence Actually Shows
A clinical review of nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) safety in geriatric adults, covering renal considerations, drug interactions, dosing, and what trials have (and haven't) proven in the 65+ population.
NMN/NR (Nicotinamide Mononucleotide/Riboside): History and Development
A timeline of NMN and NR from early NAD+ biochemistry through human trials and FDA regulatory shifts, with what the evidence shows so far.
NMN/NR Mechanism of Action: The Full NAD+ Biosynthesis Pathway Explained
A physician-level explanation of how nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) raise NAD+ levels, activate sirtuins and PARPs, and influence metabolic health.
Does State Medicaid Cover NMN or NR (Nicotinamide Mononucleotide/Riboside)?
Medicaid coverage for NMN or NR is not confirmed. Both are sold as dietary supplements, not FDA-approved drugs, and neither is approved for aging.
NMN/NR Monitoring Schedule: Labs, Exams, and Follow-Up Timeline
Evidence-based monitoring schedule for nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) supplementation, including recommended labs, exam intervals, and safety biomarkers reviewed by physicians.
NMN/NR (Nicotinamide Mononucleotide/Riboside) Off-Label Uses With Evidence Levels
A clinical review of NMN and NR off-label applications, from insulin sensitivity to cardiovascular aging, graded by human trial evidence and mechanistic plausibility.
NMN/NR Regulatory Status: US, EU, Canada, and UK Rules for Nicotinamide Mononucleotide and Riboside
NMN supplements sit in a legal gray zone: the FDA excluded NMN from the dietary supplement definition in 2022, and the EU and UK have not authorized it.
NMN/NR Storage, Stability & Shelf Life: Evidence-Based Handling Guide
NMN at 40°C is not stable long-term: unprotected powder loses 15-30% potency over 6 months at 40°C/75% RH, the ICH accelerated stability test standard.
BPC-157 for GI Healing: Off-Label Dosing Protocol, Evidence, and Clinical Considerations
BPC-157 pentadecapeptide is used off-label for GI healing. This evidence-based guide covers dosing protocols, preclinical data, safety signals, and what physicians should know before prescribing.
BPC-157 for Inflammation: Off-Label Evidence, Monitoring, and What Clinicians Need to Know
BPC-157 pentadecapeptide is used off-label for inflammation despite lacking FDA approval. Review the preclinical evidence, proposed mechanisms, monitoring requirements, and safety considerations.
BPC-157 for Tendon Repair: What the Evidence Actually Shows
A clinical evidence summary of BPC-157 pentadecapeptide for tendon repair, including preclinical trial data, proposed mechanisms, dosing protocols used in research, and what physicians should know about this off-label peptide.
CJC-1295 for Fat Loss: What the Evidence Actually Shows
A clinical review of CJC-1295 (modified GRF 1-29) for fat loss, including the limited trial data, mechanism of action through GH-axis stimulation, dosing protocols used in research, and why this peptide remains off-label with no FDA approval for any indication.
CJC-1295 for Longevity: Off-Label Dosing Protocol, Evidence, and Clinical Considerations
CJC-1295 modified GRF is used off-label for longevity. This guide covers dosing protocols, evidence quality, GH-axis physiology, safety data, and what the clinical research actually shows.
CJC-1295 for Longevity: Off-Label Evidence, Monitoring, and What Clinicians Actually Know
CJC-1295 (modified GRF 1-29) is used off-label for longevity and anti-aging. This evidence review covers the clinical data, monitoring requirements, safety signals, and what patients should discuss with their provider.
CJC-1295 for Recovery: Off-Label Evidence Summary
A clinical review of CJC-1295 (modified GRF 1-29) for recovery, including off-label evidence, GH-axis pharmacology, dosing protocols, and safety data.
Enclomiphene Citrate for Gynecomastia: Off-Label Dosing Protocol
Enclomiphene citrate is sometimes used off-label for gynecomastia. Learn about the evidence, dosing protocols, and how it compares to other SERMs like tamoxifen and raloxifene.
Enclomiphene Citrate for Gynecomastia: Off-Label Evidence Summary
A clinical evidence summary of enclomiphene citrate used off-label for gynecomastia, including mechanism of action, trial data, dosing protocols, and how it compares to clomiphene and tamoxifen.
Enclomiphene Citrate for Secondary Hypogonadism: Off-Label Dosing Protocol
Evidence-based guide to off-label enclomiphene citrate use in secondary hypogonadism, including dosing protocols, clinical trial data, and comparison to clomiphene and TRT.
Enclomiphene Citrate for Secondary Hypogonadism: Off-Label Use, Evidence, and Monitoring
Enclomiphene citrate is used off-label for secondary hypogonadism to raise testosterone while preserving fertility. What the evidence actually shows, what remains unverified, and how monitoring should be structured.
Oral Estradiol for Cognitive Decline Prevention: Off-Label Dosing Protocol
Evidence review of off-label oral estradiol for cognitive decline prevention, including dosing protocols, the critical window hypothesis, key trial data from WHIMS and KEEPS, and clinical considerations.
Oral Estradiol for Osteoporosis: Evidence Summary and Off-Label Considerations
A clinical evidence summary of oral estradiol for osteoporosis, including FDA-approved prevention indications, off-label treatment use, WHI trial data, dosing, and risk-benefit analysis.
Oral Estradiol for Osteoporosis: Off-Label Use, Risks, and Clinical Evidence
Oral estradiol is used off-label for osteoporosis prevention and treatment in postmenopausal women. Review the evidence from WHI and other trials, bone density outcomes, fracture risk reduction, and the risk-benefit tradeoffs compared to FDA-approved alternatives.
Oral Estradiol for Transgender HRT: Off-Label Dosing Protocol
Oral estradiol is off-label for feminizing therapy. See the guideline goal, the tablet label's contraindications and warnings, and clot-risk data.
Oral Estradiol for Transgender HRT: Evidence Summary and Clinical Guidance
A comprehensive evidence summary on using oral estradiol for feminizing hormone therapy in transgender women, including dosing, efficacy, safety data, and guideline recommendations.
Oral Estradiol for Transgender HRT: Monitoring, Evidence, and Clinical Guidance
Oral estradiol is widely prescribed off-label for feminizing hormone therapy in transgender women. Learn about monitoring protocols, target lab values, VTE risk, and evidence-based dosing.
Estradiol Patches for Bone Health: Label Doses and Trial Evidence
Compare estradiol patch labels and bone-density trial results, with clear distinctions between osteoporosis prevention, dose choice and fracture evidence.
Estradiol Patch for Osteoporosis: Monitoring, Evidence, and Clinical Guidance
How transdermal estradiol prevents postmenopausal bone loss, what monitoring you need on therapy, and the evidence behind dosing for skeletal protection.
Estradiol Patch for Perimenopausal Mood: Off-Label Evidence, Doses, and Monitoring
Transdermal estradiol is used off-label for perimenopausal mood symptoms. Review the clinical trial data, recommended doses, monitoring protocols, and safety considerations.
Estradiol Patch for Perimenopausal Mood: Off-Label Evidence, Risks, and Tradeoffs
Can an estradiol transdermal patch treat perimenopausal mood symptoms? We review the off-label evidence, FDA-approved indications, clinical trial data, risks, and how to talk to your provider.
Estradiol Patch for Transgender HRT: Off-Label Dosing Protocol
Evidence-based guide to using estradiol transdermal patches for feminizing hormone therapy in transgender women, including dosing protocols, monitoring, and clinical outcomes.
Estradiol Patch for Transgender HRT: Evidence Summary
A clinical evidence summary on using transdermal estradiol patches for feminizing hormone therapy in transgender women, covering dosing, safety, efficacy data, and guideline recommendations.
Finasteride for Women: Does It Work for Hair Loss?
Off-label finasteride helped hair density in postmenopausal women at doses above 1 mg; the 1 mg male dose showed no benefit. Contraindicated in pregnancy.
Finasteride for Women: Off-Label Use, Dosing, Monitoring
Finasteride isn't FDA-approved for women. The only placebo-controlled trial (1 mg) showed no benefit, and pregnancy is a contraindication.
Finasteride for Female Pattern Hair Loss: Risks, Pregnancy
Finasteride is not approved for female pattern hair loss. A placebo-controlled trial in postmenopausal women found no benefit.
Finasteride for Hirsutism: Off-Label Evidence, Risks, and Clinical Tradeoffs
Finasteride is used off-label for hirsutism in women. Review the clinical trial data, side-effect profile, pregnancy contraindication, dosing, and how it compares to spironolactone.
GHK-Cu for Cognition: What the Evidence Actually Shows
An evidence-based review of copper tripeptide GHK-Cu for cognitive function. Covers preclinical gene-expression data, animal findings, safety, and why no human trials exist for this off-label use.
GHK-Cu for Cognition: Off-Label Evidence, Protocols, and Monitoring
Copper tripeptide GHK-Cu is being explored off-label for cognitive support. Learn what the preclinical evidence shows, how clinicians monitor patients, and what labs to track.
GHK-Cu for Hair Growth: Off-Label Evidence, Risks, and Clinical Tradeoffs
Copper tripeptide GHK-Cu is used off-label for hair growth. Review the preclinical evidence, limited human data, safety risks, and how it compares to FDA-approved options like minoxidil and finasteride.
GHK-Cu for Skin Regeneration: Off-Label Evidence, Risks, and Clinical Tradeoffs
A clinical review of copper tripeptide GHK-Cu for skin regeneration, including off-label status, trial evidence, safety profile, and how it compares to FDA-approved alternatives.
Leqvio for FH: Who Guidelines Recommend It For
Leqvio is labeled for adults with HeFH and children 12 and older with HeFH or HoFH. ORION-9 showed a 47.9 percentage-point LDL-C difference vs placebo.
Ipamorelin for Fat Loss: What the Evidence Actually Shows
A clinical evidence summary of ipamorelin acetate for fat loss, including trial data, mechanism of action, dosing protocols, safety profile, and off-label status.
Ipamorelin for Longevity: Off-Label Dosing Protocol, Evidence, and Clinical Guidance
Ipamorelin acetate is used off-label for longevity and anti-aging. This evidence-based guide covers dosing protocols, growth hormone physiology, safety data, and what the clinical research actually shows.
Ipamorelin for Longevity: Off-Label Evidence, Risks, and Monitoring
Ipamorelin acetate is used off-label for longevity and anti-aging. Learn what the evidence actually shows, how clinicians monitor patients, and what blood work is required.
Ipamorelin for Recovery: Off-Label Evidence, Dosing, and Monitoring
A clinical review of ipamorelin acetate used off-label for recovery, including evidence quality, dosing protocols, required lab monitoring, and safety considerations.
Metformin for Cancer Prevention: What the Evidence Actually Shows
A clinical evidence summary of metformin's off-label use for cancer prevention, including key trials, biological mechanisms, and current guideline positions.
Metformin for Cancer Prevention: Off-Label Evidence, Monitoring, and What Clinicians Actually Know
Metformin is FDA-approved for type 2 diabetes, but observational data suggest it may reduce cancer incidence. Here is what the trials show, what remains unproven, and how to monitor patients using metformin off-label for cancer risk reduction.
Metformin for Longevity: Off-Label Dosing Protocol, Evidence, and What Clinicians Actually Prescribe
Metformin is prescribed off-label for longevity based on observational data and preclinical evidence. Here is what the clinical trials show, how physicians dose it, and what TAME will tell us.
TAME Trial Metformin Aging Status 2026 - Monitoring Guide
Metformin is not FDA-approved for aging. Two reviews describe the TAME trial, and the label calls for eGFR, hematologic and B12 checks.
Metformin for Longevity: Off-Label Evidence, Risks, and Clinical Tradeoffs
A clinical review of metformin's off-label use for longevity, including trial data, AMPK mechanisms, side effects, and who may or may not benefit from anti-aging metformin therapy.
Metformin for NAFLD: Off-Label Use, Evidence, and Monitoring
Metformin is sometimes used off-label for nonalcoholic fatty liver disease (NAFLD). Learn what the evidence shows, how monitoring works, and what guidelines recommend.
Metformin for NAFLD: Off-Label Risks, Benefits, and What the Evidence Actually Shows
Metformin is widely prescribed off-label for NAFLD, but clinical trials show limited histological benefit. Learn the real evidence, risks, tradeoffs, and better-studied alternatives.
PCOS and Metformin: Off-Label Use and Monitoring
Metformin isn't FDA-approved for PCOS but is used off-label to improve insulin sensitivity and ovulation. Learn required monitoring and dosing basics.